American Society of Clinical Oncology (ASCO). Understanding Tumor Markers. Updated 3/18/2013. Accessed at http://www.cancer.net/all-about-cancer/cancernet-feature-articles/treatments-tests-and-procedures/understanding-tumor-markers on October 24, 2013.
Associated Regional and University Pathologists (ARUP) Laboratories. ARUP’s Laboratory Test Directory. Accessed at www.aruplab.com/TestDirectory/testdirectory.jsp on October 25, 2013.
Bergamaschi S, Morato E, Bazzo M, et al. Tumor markers are elevated in patients with rheumatoid arthritis and do not indicate presence of cancer. Int J Rheum Dis. 2012;15(2):179-182.
Bigbee W, Herberman RB. Tumor markers and immunodiagnosis. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E III, eds. Cancer Medicine. 6th ed. Hamilton, Ontario: BC Decker; 2003: 209-220.
Giusti M, Sidoti M, Augeri C, Rabitti C, Minuto F. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol. 2004;150(3):299-303.
Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 Update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology. 2007;25: 5287-5312.
Hayes DF. Biomarkers. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer Principles & Practice of Oncology. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011: 694-701.
Hellström I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63:3695-3700.
Lab Tests Online. Tumor Markers. Accessed at http://labtestsonline.org/understanding/analytes/tumor-markers/start/2 on October 25, 2013.
Lee P, Pincus MR, McPherson RA. Diagnosis and management of cancer using serologic tumor markers. In: McPherson RA, Pincus MR, eds. Henry’s Clinical Diagnosis and Management by Laboratory Methods. 21st ed. Philadelphia, Pa: Saunders Elsevier; 2007: 1353-1366.
Locker GY, Hamilton S, Harris J, et al. ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer. Journal of Clinical Oncology. 2006; 24: 5313-5327.
Mayo Clinic, Mayo Medical Laboratories. Accessed at www.mayomedicallaboratories.com/index.html on October 25, 2013.
National Cancer Institute. Tumor Markers. Accessed at www.cancer.gov/cancertopics/factsheet/Detection/tumor-markers on October 25, 2013.
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Hepatobiliary cancers. V.2.2013. Accessed at www.nccn.org on October 25, 2013.
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. V.1.2014. Accessed at www.nccn.org on October 25, 2013.
Pall M, Iqbal J, Singh SK, Rana SV. CA 19-9 as a serum marker in urothelial carcinoma. Urol Ann. 2012;4(2):98-101.
Sokoll LJ, Chan DW. Biomarkers for Cancer Diagnostics. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, eds. Abeloff’s Clinical Oncology. 4th ed. Philadelphia, Pa: Churchill Livingstone; 2008: 277-282.
Zervoudis S, Peitsidis P, Iatrakis G, et al. Increased levels of tumor markers in the follow-up of 400 patients with breast cancer without recurrence or metastasis: interpretation of false-positive results. J BUON. 2007;12(4):487-492.
Last Medical Review: 10/30/2013
Last Revised: 10/30/2013